RxDoctor Payments Data

Stephanie van, MD

Physical Medicine & Rehabilitation · Baltimore, MDNPI 1225423395

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.4% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Boston Scientific at 42.2% of the total. Reporting peaked in 2019 at $346 and has fallen 95.5% since, to $16 in 2025.

$579in general payments, 2019–2025

Across 10 payments — averaging $57.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$244
  • SPR Therapeutics, Inc$176
  • Medtronic$102
  • Johnson & Johnson$27
  • Collegium Pharmaceutical, Inc.$16
  • Averitas Pharma Inc.$14

What the payments were for

  • Travel & lodging$387%
  • Food & beverage$54093%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$579 in reported general payments places this provider in the 70th percentile of 202 physical medicine & rehabilitation providers in Maryland.

See all physical medicine & rehabilitation providers in Maryland

Medicare billing

Part B allowed, 2024
$148,659
Medicare patients
195
Services billed
6,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl18$7,848
Xtampza ErOxycodone Myristate11$7,305
Lidocaine46$5,599
Oxycodone Hcl116$4,684
Pregabalin121$4,123
Gabapentin264$2,170
Duloxetine Hcl65$2,065
Diclofenac Sodium70$1,794
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen61$1,571
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl16$1,380
Baclofen86$1,066
Hydroxyzine Hcl30$981
Morphine Sulfate ErMorphine Sulfate23$924
Hydromorphone Hcl27$879
Ondansetron Hcl21$864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$16$7,30511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 202 physical medicine & rehabilitation providers in Maryland.

Other physical medicine & rehabilitation in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →